Announcement Niagen Bioscience, Inc., the leading global authority on NAD+ (nicotinamide adenine dinucleotide) with an aim on the science of healthy ageing, have shared dedicated results from the best-in-class first clinical trial officially published latest in ‘The Lancet' peer-reviewed jou...
Announcement Neurogene Inc., a clinical-level leading company built to introduce life-changing, transformative genetic medicines to families and patient groups suffering from rare neurological diseases, have proudly proved its efforts to bring updated positive interim clinical data in the pediatri...
Announcement With the end of the year, the flashback to the transformative trends has been a memorable positive change in the healthcare sector that brought new hope and modernisation upgrade to the individuals’ good health, elevating their lifestyle. The tremendous impact in the biotech and...
Announcement Centessa Pharmaceuticals plc, a leading clinical-level pharmaceutical company, has fixed the pricing value of its underwritten public offering of around 11,627,907 American Depositary Shares (ADSs). Every share has attached an ordinary share at a price rate to the public worth $21.50 ...
Announcement Dare Bioscience, Inc. is an intention-driven, accelerated biotech company completely targeting covering the gap between real-world solutions and promising science to improve women’s health will be on stage in a live webinar for the DARE to PLAY™ DIFFERENCE following its com...
Announcement Galvanize Therapeutics Inc., a leading marketing pro medical technology company featuring pulsed electric field (PEF) therapies for chronic lung disease and oncology, opted for the online platform to post its positive six-month results from its robust AFFINITY clinical trial in the med...
Announcement Repair Biotechnologies Inc. highlighted its current presentation of preclinical data proving the regression and potential of atherosclerotic plaque with REP-0003 treatment under its preclinical data at the American Heart Association’s (AHA) Scientific Sessions 2025 in New Orlean...
Announcement AN2 Therapeutics, Inc., a leading biopharmaceutical company specialising in small molecule therapeutics with its comprehensive boron chemistry platform, has fixed a research collaboration deal with the leading GSK biopharma company to discover new therapies for tuberculosis (TB). TB h...
Announcement Idorsia Ltd. has published the new evaluation, a slight improvement from the landmark Phase 3 PRECISION study, in the Journal of Hypertension with the title ‘Effects of aprocitentan on prognostically relevant ambulatory blood pressure-derived variables in resistant hypertension....
Announcement INBRAIN Neuroelectronics, a leading brain-computer interface therapeutics (BCI-Tx) company establishing graphene-related neural technologies, has entered a smart partnership with the popular Microsoft company to discover the diversified excellent use of agentic artificial intelligence...
